CindyA Posted April 30, 2014 Share Posted April 30, 2014 The US Food and Drug Administration granted accelerated approval to ceritinib (Zykadia) for the treatment of patients with metastatic ALK-positive non–small-cell lung cancer (NSCLC). About 2% to 7% percent of NSCLC patients have ALK-positive disease. - See more at: http://www.cancernetwork.com/news/fda-a ... LIVmQ.dpuf Cheryncp123, Tom Galli and Scooter49 3 Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.